We are live on ! Find out more
TAM

TFG Asset Management Portfolio holdings

AUM $635M
1-Year Est. Return 28.07%
This Fund
S&P 500
This Quarter Est. Return
+24.94%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$474M
AUM Growth
-$273M
Cap. Flow
+$1.64M
Cap. Flow %
0.35%
Top 10 Hldgs %
86.79%
Holding
46
New
9
Increased
7
Reduced
6
Closed
18

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$7.78M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.68M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$4.27M
4
RAPT
RAPT Therapeutics
RAPT
+$4.09M
5
NKTR icon
Nektar Therapeutics
NKTR
+$3.88M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$7.43M
2
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$5.92M
3
SRRK icon
Scholar Rock
SRRK
+$4.39M
4
TECX
Tectonic Therapeutic
TECX
+$3.82M
5
AXSM icon
Axsome Therapeutics
AXSM
+$2.73M

Sector Composition

Rank Sector Weight
1 Technology 71.19%
2 Healthcare 23.07%
3 Energy 5.75%
4 Miscellaneous 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$9.4B
$286M 60.3%
17,450,000
+500,000
+3% +$7.78M
KGEI
2
Kolibri Global Energy
KGEI
$209M
$27.3M 5.75%
6,934,504
-136,064
-2% -$592K
LYFT icon
3
Lyft
LYFT
$6.7B
$19.4M 4.08%
1,000,000
– –
AUTL
4
Autolus Therapeutics
AUTL
$623M
$18.9M 3.99%
9,500,000
– –
CXM icon
5
Sprinklr
CXM
$1.91B
$17.1M 3.61%
2,200,000
– –
WK icon
6
Workiva
WK
$4.31B
$12.9M 2.73%
150,000
– –
ANNX icon
7
Annexon
ANNX
$942M
$10.2M 2.15%
2,032,455
-80,000
-4% -$306K
PRAX icon
8
Praxis Precision Medicines
PRAX
$9.63B
$6.76M 1.43%
+22,952
New +$4.27M
CLDX icon
9
Celldex Therapeutics
CLDX
$3.07B
$6.62M 1.4%
243,800
-59,800
-20% -$1.58M
ARWR icon
10
Arrowhead Research
ARWR
$12B
$6.44M 1.36%
96,935
+15,094
+18% +$740K
PHVS icon
11
Pharvaris
PHVS
$2.48B
$5.4M 1.14%
194,612
– –
AXSM icon
12
Axsome Therapeutics
AXSM
$10.4B
$4.92M 1.04%
26,934
-19,522
-42% -$2.73M
DYN icon
13
Dyne Therapeutics
DYN
$4.68B
$4.85M 1.02%
247,997
+24,816
+11% +$470K
MBX
14
MBX Biosciences
MBX
$3.03B
$4.52M 0.95%
143,327
-34,513
-19% -$837K
RAPT
15
DELISTED
RAPT Therapeutics
RAPT
$4.46M 0.94%
+131,770
New +$4.09M
AGIO icon
16
Agios Pharmaceuticals
AGIO
$1.99B
$4.41M 0.93%
+162,018
New +$5.68M
IMVT icon
17
Immunovant
IMVT
$8.51B
$4.22M 0.89%
166,187
-22,192
-12% -$495K
ALKS icon
18
Alkermes
ALKS
$7.95B
$3.95M 0.83%
141,172
+51,560
+58% +$1.54M
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
$3.71M 0.78%
260,771
+139,559
+115% +$1.37M
AMLX icon
20
Amylyx Pharmaceuticals
AMLX
$3.87B
$3.3M 0.69%
272,828
+14,586
+6% +$198K
HRMY icon
21
Harmony Biosciences
HRMY
$2.28B
$3.1M 0.65%
+82,824
New +$2.72M
NKTR icon
22
Nektar Therapeutics
NKTR
$2.48B
$2.93M 0.62%
+69,287
New +$3.88M
KRYS icon
23
Krystal Biotech
KRYS
$10.4B
$2.91M 0.61%
11,814
+6,944
+143% +$1.46M
MPLT
24
MapLight Therapeutics
MPLT
$584M
$2.89M 0.61%
+164,525
New +$2.76M
SLN
25
Silence Therapeutics
SLN
$834M
$2.22M 0.47%
+365,369
New +$2.34M
1
2

Similar funds

GRR
Golden Reserve Retirement Dublin, Ohio $635M AUM 25.04% 1-Year Est. Return
GAM
Gould Asset Management Claremont, California $635M AUM 14.36% 1-Year Est. Return
MPIA
Mountain Pacific Investment Advisers Boise, Idaho $635M AUM 26.7% 1-Year Est. Return
AFG
Altiora Financial Group Lebanon, Ohio $634M AUM 13.93% 1-Year Est. Return
MWA
Martel Wealth Advisors Vancouver, Washington $636M AUM 12.74% 1-Year Est. Return
MCM
Maytus Capital Management New York $636M AUM 131.32% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
BAM
BOCHK Asset Management Hong Kong $634M AUM 64.99% 1-Year Est. Return

TFG Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, TFG Asset Management held 46 positions worth $474M, down 37% from $748M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

TFG Asset Management's Q4 2025 filing shows 9 new, 7 increased, 6 reduced and 18 closed positions. Its largest new stake was Agios Pharmaceuticals: 162,018 shares worth $4.41M. The largest sale was Tarsus Pharmaceuticals, an estimated $7.43M.

By sector, the portfolio is most concentrated in Technology at 71% of assets, up from 38% a quarter earlier, followed by Healthcare and Energy.

  • TFG Asset Management's largest Q4 2025 buy was Agios Pharmaceuticals: 162,018 shares worth $4.41M.
  • TFG Asset Management added most to UiPath in Q4 2025, an estimated $7.78M increase.
  • TFG Asset Management's biggest Q4 2025 reduction was Axsome Therapeutics, cutting an estimated $2.73M.
  • TFG Asset Management fully exited Tarsus Pharmaceuticals in Q4 2025, selling an estimated $7.43M.
  • TFG Asset Management's ten largest holdings make up 87% of its $474M portfolio in Q4 2025.
  • TFG Asset Management opened 9 new positions and closed 18 in Q4 2025.
  • TFG Asset Management's portfolio value fell 37% quarter-over-quarter to $474M.

Based on TFG Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.